These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 9884068

  • 1. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM.
    Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
    [Abstract] [Full Text] [Related]

  • 2. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
    Jakubík J, El-Fakahany EE, Dolezal V.
    Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
    [Abstract] [Full Text] [Related]

  • 3. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC, Maullu C, Onali P.
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
    Christopoulos A, Parsons AM, El-Fakahany EE.
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
    [Abstract] [Full Text] [Related]

  • 5. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
    Machová E, Jakubík J, El-Fakahany EE, Dolezal V.
    J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
    [Abstract] [Full Text] [Related]

  • 6. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
    Grant MK, El-Fakahany EE.
    J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
    [Abstract] [Full Text] [Related]

  • 7. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 8. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW, Cohen ML.
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [Abstract] [Full Text] [Related]

  • 9. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
    Jordan S, Chen R, Koprivica V, Hamilton R, Whitehead RE, Tottori K, Kikuchi T.
    Eur J Pharmacol; 2005 Jul 11; 517(3):165-73. PubMed ID: 15985260
    [Abstract] [Full Text] [Related]

  • 10. SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
    Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, Price GW.
    Br J Pharmacol; 1998 Sep 11; 125(1):202-8. PubMed ID: 9776361
    [Abstract] [Full Text] [Related]

  • 11. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ.
    J Pharmacol Exp Ther; 2002 Nov 11; 303(2):815-22. PubMed ID: 12388668
    [Abstract] [Full Text] [Related]

  • 12. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
    Watson JM, Hunter AJ, Brown AM, Middlemiss DN.
    Eur J Pharmacol; 1999 Apr 01; 370(1):69-77. PubMed ID: 10323282
    [Abstract] [Full Text] [Related]

  • 13. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
    Scott C, Langmead CJ, Clarke KL, Wyman P, Smith PW, Starr KR, Dawson LA, Price GW, Hagan JJ, Watson J.
    Neuropharmacology; 2006 Jun 01; 50(8):984-90. PubMed ID: 16546225
    [Abstract] [Full Text] [Related]

  • 14. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
    Christopoulos A, Pierce TL, Sorman JL, El-Fakahany EE.
    Mol Pharmacol; 1998 Jun 01; 53(6):1120-30. PubMed ID: 9614217
    [Abstract] [Full Text] [Related]

  • 15. Selectivity profile of muscarinic toxin 3 in functional assays of cloned and native receptors.
    Olianas MC, Ingianni A, Maullu C, Adem A, Karlsson E, Onali P.
    J Pharmacol Exp Ther; 1999 Jan 01; 288(1):164-70. PubMed ID: 9862767
    [Abstract] [Full Text] [Related]

  • 16. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC.
    Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660
    [Abstract] [Full Text] [Related]

  • 17. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, Swedberg MD, Suzdak PD, Sauerberg P.
    J Pharmacol Exp Ther; 1994 Apr 15; 269(1):271-81. PubMed ID: 7909557
    [Abstract] [Full Text] [Related]

  • 18. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
    Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN.
    Br J Pharmacol; 1999 Apr 15; 126(7):1620-4. PubMed ID: 10323594
    [Abstract] [Full Text] [Related]

  • 19. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
    Oz M, Zhang L, Rotondo A, Sun H, Morales M.
    Synapse; 2003 Dec 15; 50(4):303-13. PubMed ID: 14556235
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue.
    Salah-Uddin H, Thomas DR, Davies CH, Hagan JJ, Wood MD, Watson JM, Challiss RA.
    J Pharmacol Exp Ther; 2008 Jun 15; 325(3):869-74. PubMed ID: 18322150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.